Analysis of Serum Concentration of Carbamazepine in 381 Cases

LI Yu-zhen,CHEN Ri-lai,LI Heng-mei,LIU Xin-yu,LI Cheng,ZENG Fan-tao,WANG Man-lin

DOI: https://doi.org/10.3321/j.issn:1001-5213.2009.13.018

2009-01-01

Abstract:OBJECTIVE To analyze the monitoring results of carbamazepine serum concentration in 381 cases of 347 pa-tients. METHODS The carbamazepine serum concentration was measured by fluorescence polarization immunoassay. The car-bamazepine serum concentration in 381 cases was compared and analyzed and the clinical effect and adverse drug reaction of the patients were observed. RESULTS There were 311 cases(82. 1%) whose carbamazepine serum concentration were between 4 and 12 mg·L-1. Among 311 samples, there were 274 cases who were used with carbamazepine separately and 37 cases who used combination carbamazepine with other antiepileptic drugs, there were 91.6% (285/311)of them whose epilepsy were controlled on the whole or made betterand 3.9% (12/311)of them who appeared adverse drug reaction. There were 51 cases (13.4%) whose carbamazepine serum concentration were less than 4 μg·mL-1. There were 19 cases(5.0%) whose carbam-azepine serum concentration were more than 12 mg·L-1 and 84.2% (16/19) of them appeared serve adverse drug reaction. CONCLUSION It is reasonable that the therapeutic window of carbamazepine serum concentration is between 4 and 12 μg·mL-1. The therapeutical drug monitoring of carbamazepine is the important measure which ensures the clinical effect and safety in the medical care.